Cara Therapeutics Inc. (CARA) announced results from its Phase 2b trial of CR845, in patients with osteoarthritis of the knee or hip, after the bell Thursday. Patients who received the 5.0 mg dose experienced a 39 percent reduction in mean joint pain score. Patients on the 1.0 mg and 2.5 mg doses did not exhibit significant reductions in mean joint pain scores.
from RTT - Before the Bell http://ift.tt/2uh0bv8
via IFTTT
No comments:
Post a Comment